Skip to main content
SpringerLink
Log in

Carcinoma in situ and treatment options

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Carcinoma in situ (CIS) is a high-grade and aggressive manifestation of transitional-cell carcinoma of the bladder that has a highly variable course. The treatment of CIS has undergone dramatic changes since this malignancy was first recognized. While cystectomy was once recommended as the initial treatment of choice, recognition of the highly variable prognosis and the uniformly high response rate to intravesical BCG has prompted a more conservative approach to management. Patients who fail BCG immunotherapy without evidence of progression may yet be candidates for intravesical chemotherapy, photodynamic therapy, or alternative immunotherapies such as alpha-2b interferon, bromopirimine, or keyhole limpet haemocyanin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Althausen, A. F., Prout, G. R., Daly, J. J.: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.J. Urol., 116 575 (1976).

    PubMed  CAS  Google Scholar 

  2. Lum, B. L., Torti, F. M.: Therapeutic approaches including interferon to carcinoma in situ of the bladder.Cancer Treatment Rev., 12(Suppl.), 45 (1985).

    Google Scholar 

  3. Torti, F. M., Lum, B. L.: Superficial bladder cancer: Risk of recurrence and potential role for interferon therapy.Cancer 59, 613 (1987).

    Article  PubMed  CAS  Google Scholar 

  4. Farrow, G. M., Utz, B. C., Rife, C. C.: Clinical observations on 69 cases of in situ carcinoma of the urinary bladder.Cancer Res., 37, 2794 (1977).

    PubMed  CAS  Google Scholar 

  5. Melamed, M. R., Voutsa, N. G., Grabstald, H.: Natural history and clinical behavior of in situ carcinoma of the human urinary bladder.Cancer, 17, 1533 (1964).

    Article  PubMed  CAS  Google Scholar 

  6. Eisenberg, R. B., Roth, R. B., Schweinsberg, M. H.: Bladder tumors and associated proliferative mucosal lesions.J. Urol., 84, 544 (1960).

    PubMed  CAS  Google Scholar 

  7. Schade, R. O., Swinney, J.: The association of urothelial atypism with neoplasia: Its importance in treatment and prognosis.J. Urol., 109, 619 (1973).

    PubMed  CAS  Google Scholar 

  8. Soloway, M. S., Murphy, W., Rao, M. K., Cox, C.: Serial multiple-site biopsies in patients with bladder cancer.J. Urol., 120, 57 (1978).

    PubMed  CAS  Google Scholar 

  9. Farrow, G. M., Utz, D. C.: Observations on microinvasive transitional cell carcinoma of the urinary bladder.Clin. Oncol., 1, 609 (1982).

    Google Scholar 

  10. Utz, D. C., Hanash, K. A., Farrow, G. M.: The plight of the patient with carcinoma in situ of the bladder.J. Urol., 103, 160 (1970).

    PubMed  CAS  Google Scholar 

  11. Weinstein, R. S., Miller, A. W., Pauli, B. U.: Carcinoma in situ: Comments on the pathobiology of a paradox.Urol. Clin. North. Am., 7, 523 (1980).

    PubMed  CAS  Google Scholar 

  12. Utz, D. C., Zincke, H.: Carcinoma in situ of the urinary tract.Urol. Clin. North. Am., 11, 535 (1984).

    Google Scholar 

  13. Utz, D. C., Farrow, D. M.: Management of carcinoma in situ of the bladder: A case of surgical management.Urol. Clin. North. Am., 7, 533 (1980).

    PubMed  CAS  Google Scholar 

  14. Bowen, J. T.:Cutan. Dis. Syph., 30, 241 (1912) Cited in: Melicow, M. M., Hollowell, J. W. [17].

    Google Scholar 

  15. Jensener, M.:Arch. Dermatol. Syph., 134, 361 (1921).

    Article  Google Scholar 

  16. Melicow, M. M.: Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy.J. Urol., 68, 261 (1952).

    PubMed  CAS  Google Scholar 

  17. Melicow, M. M., Hollowell, J. W.: Intra-urothelial cancer: Carcinoma in situ, Bowen's disease of the urinary system: Discussion of 30 cases.J. Urol., 68, 736 (1952).

    Google Scholar 

  18. Farrow, G. M.: Pathologist's role in bladder cancer.Semin. Oncol., 6, 198 (1979).

    PubMed  CAS  Google Scholar 

  19. Klein, F. A., Herr, H. W., Sogani, T. C., Whitmore, W. F. Jr., Melamed, M. R.: Detection and follow-up of carcinoma of the urinary bladder by flow cytometry.Cancer, 50, 389 (1982).

    Article  PubMed  CAS  Google Scholar 

  20. Althausen, A. F., Prout, G. R. Jr., Daly, J. J.: Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ.J. Urol., 116 575 (1976).

    PubMed  CAS  Google Scholar 

  21. Prout, G. R. Jr., Koontz, W. W. Jr., Coombs, L. J., Hawkins, I. R., Friedel, G. H.: Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not receive thiotepa.J. Urol., 130 677 (1983).

    PubMed  Google Scholar 

  22. Kurth, K., Vijah, W. J. F., Kate, F. T., Bogdanowicz, J. F., Carpentier, P. J., van Reyswoud, I.: Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder.J. Urol., 146, 1508 (1991).

    PubMed  CAS  Google Scholar 

  23. Lamm, D. L., Blumensten, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, B., Stanisic, T. H., Smith, J. Jr., Sullivan, J., Sarosdy, M. F., Grissman, J. D., Coltman, C. A.: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.N. Engl. J. Med., 325, 1205 (1991).

    Article  PubMed  CAS  Google Scholar 

  24. Robinson, M. R. G., Richards, B., Adib, R., Akdas, A., Rigby, C. C., Pugh, R. C. B.: Intravesical BCG in the management of cell tumors of the bladder: A toxicity study. Bladder Tumors and other Topics in Urological Oncology. Plenum Press Ltd., New York 1980.

    Google Scholar 

  25. Bretton, P. R., Herr, H. W., Whitmore, W. F. Jr., Badalament, R. A., Kimmel, M., Provet, J., Oettgen, H. F., Melamed, M. R., Fair, W. R.: Intravesical Bacillus Calmette-Guérin therapy for in situ transitional cell carcinoma involving the prostatic urethra.J. Urol., 141, 853 (1989).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Marmara University School of Medicine, Istanbul, Turkey

    M. Erton, Y. Ilker & A. Akdaş

Authors
  1. M. Erton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. Ilker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Akdaş
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erton, M., Ilker, Y. & Akdaş, A. Carcinoma in situ and treatment options. International Urology and Nephrology 28, 33–42 (1996). https://doi.org/10.1007/BF02550135

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02550135

Keywords

Search

Navigation